Aug
A study published looking at US soldiers injured in Iraq shows the need for investment in emerging treatment technologies for serious injuries both by the UK military and the NHS.
All of the patients included in the study were suffering from combat injuries classed as grade III tibial fractures, 68% of which were from blasts such as road side bombs.
The soldiers, split retrospectively into two groups and those receiving the rhBMP-2 protein had remarkable results; a strikingly improved rate of union, a reduced rate of infection and a much lower rate of reoperation. These results display a ‘compelling argument for the continued use of such technologies’ in treatment of soldiers returning from combat zones and other patients, showing that the research is the most significant trauma contribution arising from the Iraq war.
A Freedom of Information Request was lodged with the Ministry of Defense for information on whether this treatment has been used on British Soldiers, but so far no answer has been forthcoming. Discussion has been ongoing about the variance in treatments between UK and US soldiers injured in combat and most likely the study will add to debates about the availability for emerging treatments and current climate cost-benefits analyses.
Read the article
The Journal of Bone and Joint Surgery - British Volume is a world leading orthopaedics journal with an Impact Factor of 1.868
JBJS-Br publishes twelve issues a year of high-quality, peer-reviewed research, overseen by an international editorial board led by Editor James Scott
The Journal was first published in 1948 by The British Editorial Society of Bone and Joint Surgery, a registered charity (No. 209299), with the object of the advancement and improvement of education in orthopaedic surgery and allied branches of surgery and the diffusion of knowledge of new and improved methods of teaching and practicing orthopaedic surgery in all its branches
You can find out more about The Journal at http://www.jbjs.org.uk
Journal of Bone and Joint Surgery